173 related articles for article (PubMed ID: 29192278)
1. Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation.
Holst S; Belo AI; Giovannetti E; van Die I; Wuhrer M
Sci Rep; 2017 Nov; 7(1):16623. PubMed ID: 29192278
[TBL] [Abstract][Full Text] [Related]
2. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
3. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma.
Mancera-Arteu M; Giménez E; Balmaña M; Barrabés S; Albiol-Quer M; Fort E; Peracaula R; Sanz-Nebot V
J Proteomics; 2019 Mar; 195():76-87. PubMed ID: 30641231
[TBL] [Abstract][Full Text] [Related]
4. Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation.
Chugh S; Meza J; Sheinin YM; Ponnusamy MP; Batra SK
Br J Cancer; 2016 Jun; 114(12):1376-86. PubMed ID: 27187683
[TBL] [Abstract][Full Text] [Related]
5. Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imaging.
Casadonte R; Kriegsmann M; Perren A; Baretton G; Deininger SO; Kriegsmann K; Welsch T; Pilarsky C; Kriegsmann J
Proteomics Clin Appl; 2019 Jan; 13(1):e1800046. PubMed ID: 30548962
[TBL] [Abstract][Full Text] [Related]
6. Glycoproteins and glycoproteomics in pancreatic cancer.
Pan S; Brentnall TA; Chen R
World J Gastroenterol; 2016 Nov; 22(42):9288-9299. PubMed ID: 27895417
[TBL] [Abstract][Full Text] [Related]
7. Differential
Zhang T; van Die I; Tefsen B; van Vliet SJ; Laan LC; Zhang J; Ten Dijke P; Wuhrer M; Belo AI
Front Oncol; 2020; 10():732. PubMed ID: 32582529
[TBL] [Abstract][Full Text] [Related]
8. ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer.
Hofmann BT; Stehr A; Dohrmann T; Güngör C; Herich L; Hiller J; Harder S; Ewald F; Gebauer F; Tachezy M; Precht C; Izbicki JR; Bockhorn M; Wagener C; Wolters-Eisfeld G
Clin Cancer Res; 2014 Dec; 20(23):6117-26. PubMed ID: 25320359
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
Rodriguez E; Boelaars K; Brown K; Madunić K; van Ee T; Dijk F; Verheij J; Li RJE; Schetters STT; Meijer LL; Le Large TYS; Driehuis E; Clevers H; Bruijns SCM; O'Toole T; van Vliet SJ; Bijlsma MF; Wuhrer M; Kazemier G; Giovannetti E; Garcia-Vallejo JJ; van Kooyk Y
Commun Biol; 2022 Jan; 5(1):41. PubMed ID: 35017635
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
11. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma.
Wente MN; Gaida MM; Mayer C; Michalski CW; Haag N; Giese T; Felix K; Bergmann F; Giese NA; Friess H
Int J Oncol; 2008 Aug; 33(2):297-308. PubMed ID: 18636150
[TBL] [Abstract][Full Text] [Related]
12. The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells.
Giannuzzo A; Pedersen SF; Novak I
Mol Cancer; 2015 Nov; 14():203. PubMed ID: 26607222
[TBL] [Abstract][Full Text] [Related]
13. The detection of tumor location and lymph node metastasis by aberrant NXPH1 and NXPH2 expressions in pancreatic ductal adenocarcinomas.
Jin JS; Tsai WC
Chin J Physiol; 2016 Dec; 59(6):348-354. PubMed ID: 27817196
[TBL] [Abstract][Full Text] [Related]
14. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma.
Sperveslage J; Frank S; Heneweer C; Egberts J; Schniewind B; Buchholz M; Bergmann F; Giese N; Munding J; Hahn SA; Kalthoff H; Klöppel G; Sipos B
Int J Cancer; 2012 Aug; 131(4):E371-81. PubMed ID: 22020953
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
16. Integrated Systems Analysis of the Murine and Human Pancreatic Cancer Glycomes Reveals a Tumor-Promoting Role for ST6GAL1.
Kurz E; Chen S; Vucic E; Baptiste G; Loomis C; Agrawal P; Hajdu C; Bar-Sagi D; Mahal LK
Mol Cell Proteomics; 2021; 20():100160. PubMed ID: 34634466
[TBL] [Abstract][Full Text] [Related]
17. Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species.
Yokoyama M; Tanuma N; Shibuya R; Shiroki T; Abue M; Yamamoto K; Miura K; Yamaguchi K; Sato I; Tamai K; Satoh K
Int J Oncol; 2018 Mar; 52(3):881-891. PubMed ID: 29393401
[TBL] [Abstract][Full Text] [Related]
18. Loss of MTSS1 results in increased metastatic potential in pancreatic cancer.
Zeleniak AE; Huang W; Brinkman MK; Fishel ML; Hill R
Oncotarget; 2017 Mar; 8(10):16473-16487. PubMed ID: 28146435
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma.
Waragai Y; Suzuki R; Takagi T; Sugimoto M; Asama H; Watanabe K; Kikuchi H; Hikichi T; Masamune A; Kang Y; Fleming JB; Ohira H
Pancreatology; 2016; 16(6):1044-1050. PubMed ID: 27665173
[TBL] [Abstract][Full Text] [Related]
20. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
